For about ten years the advice has been the same: eat less, move more, come back next year. You did, more or less, and the scale and the lab sheet drifted the wrong way anyway. The change was slow enough that nobody raised an alarm and steady enough that you reached your own quiet conclusion about whose fault it was. Now you are reading about GLP-1 medication and a membership that costs $299 a month. Before anything else you want the GLP-1 medication cost settled, because a monthly fee that opens the door to a bill you cannot carry helps no one.
The medication sits outside the membership. If a clinician prescribes one, the prescription goes to the pharmacy you choose and you pay that pharmacy's own price; GoodLife Health sets nothing, sees nothing and takes nothing on it. As of September 2026, the manufacturers' own self-pay prices ran from $149 a month for the Wegovy pill at lower doses to $449 a month for Zepbound vials at higher doses. Whether insurance pays any of that is between you, your plan and the pharmacy, and no one can promise it. A prescription is a clinical decision made after your labs are read, so it may not happen at all.
What follows is the longer answer: why the real number is hard to find, what each bill covers, what the membership will not do, and who should not join.
- Medication is billed by the pharmacy you choose, at its own price, separately from the $299 membership.
- September 2026 self-pay: Wegovy pens $199 for two introductory fills for new patients, then $349; Wegovy pill from $149; Zepbound vials $299 to $449.
- The membership fee is the same for every molecule and every dose, and GoodLife Health takes nothing on medication.
- Whether any medication is prescribed is a clinician's decision after labs, and insurance coverage is never promised.
- $598 at sign-up covers two months: refunded in full if you are not accepted, non-refundable once you are.
Ten years of the same advice, and the test nobody ran
The pattern may be familiar in every detail. You had a physical every year or two, your weight rose a few pounds at a time, and your fasting glucose went from fine to borderline to something to keep an eye on. Each visit closed with the same two words, diet and exercise, said kindly and quickly by someone with a short appointment and a full waiting room.
You tried. Perhaps you counted calories for a while, cut out bread, or walked every morning until the morning you did not. Some of it worked for a season. Then the weight came back, and the next appointment repeated the advice in the same tone, which made it sound like a verdict on your effort. Over enough years it becomes easy to stop asking questions at the doctor's office, on the assumption that the answer is already known and the answer is you.
What those appointments did not include, in your case, was a measurement that might have explained the pattern. Glucose was checked; insulin resistance was not. Fasting insulin can rise for years before glucose moves, so a glucose result that looks acceptable says little about the strain underneath it. The conclusion you reached about yourself was built on a test that left out the most relevant number. That does not prove the story is different for you, but it does mean the question was never properly asked.
Meanwhile GLP-1 medication is everywhere. Advertisements quote $99 a month, $149, $299. A friend mentions what she pays, and a coworker mentions a different figure he heard. Every number seems to come with a footnote you cannot find, and none of them tells you what you, with your labs and your pharmacy and your insurance, would actually be charged.
The worry underneath the cost question is specific. You fear paying to join, being prescribed something, and then finding that the medication costs more than you can manage, so that the attempt turns into one more thing that did not work. That fear is reasonable. You handle it by seeing every part of the bill before you commit to any part of it.
Why the price you see is seldom the price you pay
Any plan for GLP-1 therapy carries three costs: the clinical care that decides whether a medication is right and then manages it, the medication itself, and the lab work that shows whether anything is improving. GoodLife Health's comparison of GLP-1 telehealth costs states it as a formula: the true monthly cost is the clinical fee plus the medication plus the labs, and any comparison missing one of the three is marketing. Most advertised prices show you one of the three and leave you to discover the other two.
The medication is the part that moves. Its price depends on the molecule, the form (a pill, a pen or a vial), the dose and the channel that sells it. Advertised prices tend to be starting-dose prices, and as the comparison guide notes, the maintenance dose often costs more than anything on the pricing page. A figure quoted for your first month can be a poor guide to your sixth.
Some manufacturers now sell directly to self-pay patients and publish their prices, which gives you fixed reference points. As of September 2026, NovoCare listed Wegovy pens at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after that, with the Wegovy pill from $149 a month at lower doses. Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose. Those prices buy the drug alone, with no labs and no clinician reading the results.
Advertised prices also mislead because of where a company earns its money. The Aligned Medicine guide describes a common telehealth structure: a low membership on the pricing page and the margin inside the medication, through a spread on the molecule, an upcharge when a patient moves from semaglutide to tirzepatide, and another as the dose climbs. Under that arrangement the business earns more as your prescription grows. Nobody needs bad intentions for that to shape what gets recommended; the structure produces the preference by itself, and the preference is invisible on the pricing page.
Insurance adds uncertainty of its own. Whether your plan pays for a GLP-1 medication is decided between you, your plan and your pharmacy. Prior authorization, when a plan requires it, is the pharmacy's process. GoodLife Health does not run it, speed it up or claim it will succeed, and it does not promise that any medication will be covered, because none of that is in its hands.
The lowest prices you see often belong to a different product. Pharmacy-made copies of GLP-1 molecules, called compounded GLP-1, are sold through apps at around $99 a month, and the comparison guide prices them in a separate table because they are a separate product class from the FDA-approved branded medications. The facts are on the record: the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, and the manufacturers have taken legal action over copies of their products. Whoever writes a prescription carries the responsibility for it on their license. GoodLife Health does not prescribe compounded GLP-1, so if your decision depends on the lowest monthly figure for a GLP-1 molecule, the cheapest number you have seen is not one you will find here.
Under all of this sits a question no price list can answer: whether you need medication at all, and if so which one. For someone whose insulin resistance has never been measured, that is a lab question before it is a pharmacy question, and it is the step that ten years of appointments skipped.
Fasting insulin can rise for years before glucose moves, so a normal glucose result does not settle the question of insulin resistance. Whether any medication is indicated is decided by a clinician after the labs are read.
Two bills, and what each one pays for
GoodLife Health is clinician-led precision direct primary care for Cardiometabolic Optimization: diagnosis first, then treatment, then the long haul. The membership is $299 a month, month to month. At sign-up, $598 is charged to cover the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable. The membership fee is generally eligible for HSA or FSA pre-tax dollars.
That fee covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year, every result in your hands, asynchronous messaging with the care team, and video visits. If your insulin resistance has gone unmeasured, the quarterly labs are the reason to start here. The question gets asked, the answer is in your hands, and the next panel shows whether the answer has changed.
The medication is unbundled. When a clinician judges a medication clinically indicated, the prescription goes to the pharmacy you choose, at that pharmacy's own price, and anything a pharmacy bills you follows that pharmacy's own return and refund policy. GoodLife Health prescribes branded, FDA-approved medication only. For GLP-1 therapy that means Wegovy, Zepbound, Mounjaro or Ozempic, and any FDA-approved medication a clinician judges indicated can go to your pharmacy. The membership fee does not change with the medication or the dose. There is no molecule upcharge and no dose upcharge, so your clinician's recommendation never changes what GoodLife Health is paid.
Your clinician's recommendation never changes what GoodLife Health is paid.
That changes the cost conversation you can have. Because nothing in the business depends on what you are prescribed, you can ask your clinician directly which option is likely to cost least at your pharmacy, whether a pill or an injectable suits your budget, and whether a lower-priced channel exists for your dose. The Aligned Medicine guide gives one example: Zepbound and Mounjaro are the same molecule, tirzepatide, and a cash-pay patient can be pointed to whichever costs less. The decision about what is indicated stays clinical. The price comparison is something you are free to raise, and nobody on the other side of the table profits from steering it.
Manufacturers' self-pay prices, September 2026
| Product | Channel | Published price |
|---|---|---|
| Wegovy pens, first two fills | NovoCare | $199 a month (introductory offer for new patients through December 2026) |
| Wegovy pens, after the first two fills | NovoCare | $349 a month |
| Wegovy pill, lower doses | NovoCare | From $149 a month |
| Zepbound vials | LillyDirect | $299 to $449 a month, depending on dose |
Over a year, the membership is $3,588. The medication, if one is prescribed, sits on top of that at your pharmacy's price, and that price depends on what is prescribed and at what dose. The comparison guide works the full monthly figure through at August 2026 published prices and lands between $448 all-in on an oral entry dose and $748 at injectable maintenance, using the lowest channel price for each dose. Prices have moved since then and will move again, which is why every number here carries its date. Your own figure depends on what your labs show, what your clinician judges indicated, and what your pharmacy charges.
The membership also has limits you should know before paying anything. It does not guarantee a prescription; that is a clinician's decision. It does not promise weight loss or any particular result. It does not replace health insurance: it pairs with insurance for catastrophic coverage and replaces the primary-care relationship. It does not promise that a medication will be covered or that a prior authorization will succeed. And it does not lower the medication price by switching you to a compounded copy, because it does not prescribe them.
What to weigh before you check
After years of assuming the fault was yours, it is worth being careful about what you expect a membership to do. It will not undo the decade, and it will not hand you a number on the scale. It measures what was not measured, puts the results in your hands, and gives you a clinician who can talk about medication, including what it will cost you, with no financial stake in the answer.
One part of the cost is fixed and one is not. The membership is $598 at sign-up for the first two months, then $299 a month, or $3,588 for a year. The medication runs from nothing, if none is indicated, to whatever your pharmacy charges for what is prescribed, with the September 2026 manufacturer prices above as published reference points. Insurance may change that second part for you, or it may not, and nobody can tell you which in advance.
The model sits where it does on purpose. At one end of the market is the concierge practice at $20,000 a year; at the other is the compounded app at $99 a month. GoodLife Health sits between them, and says so, because it is built for people who want a clinician reading their labs and branded medication where it is indicated.
The path is short and in a fixed order: the eligibility check, the intake, the checkout, then a clinician's review. Not everyone is accepted. If you are not, the $598 is refunded in full; if you are, the first two months are non-refundable. The check is the first step toward finding out whether any of this applies to you.
Who this is not for
If what you want is the lowest possible monthly price for a GLP-1 molecule, this is the wrong place. The $99-a-month compounded app exists for that buyer, and GoodLife Health neither competes with it on price nor prescribes what it sells. If you want a guaranteed prescription, a promised amount of weight loss, or a company that will tell you in advance that your insurance will pay, the membership offers none of those. If you hope to drop your health insurance, this does not replace it. And if your budget has no room for both a $299 monthly fee and a separate pharmacy bill, it is better to know that before you start than to discover it in the third month.
Related Reading
- The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison
- Aligned Medicine: How Zero-Markup Healthcare Actually Works
References
- NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
- Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss